Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Szucs

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
The Journal of Antimicrobial Chemotherapy|July 6, 2000
The socio-economic burden of influenzaT Szucs
Vaccine|February 23, 2000
Cost-benefits of vaccination programmesT Szucs
Drugs|January 1, 1991
Cilazapril. A reviewT Szucs
Vaccine|February 23, 2000
Cost-effectiveness of hepatitis A and B vaccination programme in GermanyT Szucs
European Journal of Cancer Care|July 23, 2013
Geographic disparities in access to cancer care: do patients in outlying areas talk about their access problems to their general practitioners and medical oncologists and how does that impact on the choice of chemotherapy?P Groux, T Szucs
Cardiology|January 1, 1992
Cilazapril: an overview of its efficacy and safety in hypertensionT Szucs, A Schneeweiss
Infection|May 28, 2009
Reducing the burden of influenza-associated complications with antiviral therapyB R Ruf, T Szucs
Praxis|June 22, 2001
[Is the general practice laboratory medically and economically valuable?]I Beeler, T Szucs, F Gutzwiller
Medizinische Klinik (Munich, Germany : 1983)|March 20, 2001
[Public health costs of influenza in Germany 1996- a cost-of-illness analysis]T Szucs, M Behrens, T Volmer
Medizinische Klinik (Munich, Germany : 1983)|May 15, 1996
[Public health economic evaluation of screening for APC resistance (Leiden mutation) in new oral contraceptive users]T Szucs, D Osterkorn, W Schramm
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
The Journal of Antimicrobial Chemotherapy|July 6, 2000
The socio-economic burden of influenzaT Szucs
Vaccine|February 23, 2000
Cost-benefits of vaccination programmesT Szucs
Drugs|January 1, 1991
Cilazapril. A reviewT Szucs
Vaccine|February 23, 2000
Cost-effectiveness of hepatitis A and B vaccination programme in GermanyT Szucs
European Journal of Cancer Care|July 23, 2013
Geographic disparities in access to cancer care: do patients in outlying areas talk about their access problems to their general practitioners and medical oncologists and how does that impact on the choice of chemotherapy?P Groux, T Szucs
Cardiology|January 1, 1992
Cilazapril: an overview of its efficacy and safety in hypertensionT Szucs, A Schneeweiss
Infection|May 28, 2009
Reducing the burden of influenza-associated complications with antiviral therapyB R Ruf, T Szucs
Praxis|June 22, 2001
[Is the general practice laboratory medically and economically valuable?]I Beeler, T Szucs, F Gutzwiller
Medizinische Klinik (Munich, Germany : 1983)|March 20, 2001
[Public health costs of influenza in Germany 1996- a cost-of-illness analysis]T Szucs, M Behrens, T Volmer
Medizinische Klinik (Munich, Germany : 1983)|May 15, 1996
[Public health economic evaluation of screening for APC resistance (Leiden mutation) in new oral contraceptive users]T Szucs, D Osterkorn, W Schramm
Pageof 4